Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4GD | ISIN: US02155X2053 | Ticker-Symbol: PBN0
Siehe auch ALTERITY THERAPEUTICS LIMITED
NASDAQ
27.06.25 | 21:47
4,065 US-Dollar
+3,70 % +0,145
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ALTERITY THERAPEUTICS LIMITED ADR Chart 1 Jahr
5-Tage-Chart
ALTERITY THERAPEUTICS LIMITED ADR 5-Tage-Chart

Aktuelle News zur ALTERITY THERAPEUTICS LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAlterity-CEO wird Unternehmensupdate zur ATH434-Entwicklung geben2
MoALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
MoALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics to Provide Corporate Update in Fireside Chat2
MoALTERITY THERAPEUTICS LIMITED: Alterity CEO to Provide Corporate Update on ATH4341
23.05.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
12.05.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Prominently Featured at the International MSA Congress1
07.05.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress2
ALTERITY THERAPEUTICS LIMITED ADR Aktie jetzt für 0€ handeln
07.05.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
07.05.FDA grants fast track status to Alterity's multiple system atrophy treatment1
05.05.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy622- Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA - MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics...
► Artikel lesen
05.05.Monday's HotCopper Trends: | Alterity's FDA tick, Gold Road snapped up | May 5, 20252
05.05.Alterity wins FDA fast-track for ATH434 - but with 9B shares on issue, impact diluted3
30.04.ALTERITY THERAPEUTICS LIMITED: Appendix 4C - Q3 FY25 Quarterly Cash Flow Report1
28.04.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
28.04.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium2
17.04.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
10.04.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting4
10.04.Alterity's ATH434 Shows Promise in MSA1
07.04.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer4
03.04.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting1
Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1